Goodbody Health Inc. - Goodbody products on FSA Novel Foods Register
RNS Number : 7928G
Goodbody Health Inc.
31 March 2022
 

31 March 2022

Goodbody Health Inc.
("Goodbody Health", or the "Company")

Goodbody Health products included on FSA Novel Foods Register

 

Goodbody Health (AQSE: GDBY) is pleased to announce that, following the UK Food Standard Agencies (FSA) publication of the Novel Foods approved list for CBD, the Company's application has been approved by the FSA to the next stage of the Novel Foods submission, being the publication of the FSA CBD Products register. The status of 'Awaiting Evidence' means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress to the final Validated status.

 

The Company welcomes this increased compliance in the sector as the new regulations ensure that only fully compliant products are placed on the market. Those not included on these FSA CBD products Novel Food register will have to be taken off sale. Goodbody Health is now well placed to continue its growth in the CBD market as this process restricts the market to fewer competitors, as many did not meet the criteria. Consumers can visit https://ukcbdlist.com/, a site run by the Association for the Cannabinoid Industry (ACI), to see if a brand is compliant.

 

The Company's extraction facility is HACCP, GMP and ISO 22000 certified and its laboratory is UKAS accredited against ISO 17025 international standard. Goodbody Health works closely with relevant regulatory bodies (FSA, Home Office, Trading Standards). Goodbody Health provides CBD extraction into isolate and distillate, manufacturing of CBD food supplements (oils, capsules, gummies, etc), cosmetics, and has a UKAS accredited analytical laboratory testing CBD products for potency and contaminants such as heavy metals, residual solvents, pesticides and microbials. In managing the whole production process, the Company tests the products at every stage of manufacturing, from extraction to the consumer product, ensuring all the products are of the highest quality.

 

Geremy Thomas, Executive Chairman, said: "The progression so far is very welcome, as after a significant amount of work and investment over the last 2 years, we can demonstrate our ambition of best quality, best price, guaranteed. We control every step of the process from extraction to shelf, and test through our accredited laboratory, to ensure every product that is made has achieved our 'Gold Standard', demonstrating that the Company meets legal and regulatory requirements."

 

For further information:

Marc Howells

Chief Executive Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

enquiries@goodbodyhealth.com

 www.goodbodyhealth.com

Anne Tew

Chief Financial Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

enquiries@goodbodyhealth.com

 www.goodbodyhealth.com

 

 

 

AQSE Corporate Adviser

Arden Partners plc

Antonio Bossi / George Morgan

+ 44 (0) 20 7614 5900 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXFFLFXLXLXBBF ]]>